PSMA PET in Biochemical Recurrence
Detection rates by PSA, standard pitfalls, and impact on management
Quick Answer
PSMA PET is the imaging standard for biochemical recurrence of prostate cancer after definitive therapy, localizing disease when conventional imaging is negative — often at low PSA. Detection rate rises steeply with PSA and shorter PSA doubling time. Its value is directing salvage therapy (local vs nodal vs distant), but it demands fluency in the benign and non-prostatic causes of PSMA uptake to avoid a single false-positive focus upstaging a patient out of curative salvage.
Background & Clinical Importance
After radical prostatectomy (recurrence often defined as PSA ≥ 0.2 ng/mL and rising) or radiotherapy (nadir + 2 ng/mL, "Phoenix"), a rising PSA signals recurrence without telling you where. PSMA PET converts that biochemical signal into an anatomic map, changing management in a substantial proportion of patients — from empiric escalation to targeted salvage radiotherapy or systemic therapy.
Detection Rate by PSA
Detection increases with PSA level and with shorter PSA doubling time. Approximate stratified detection rates from prospective studies:
| PSA (ng/mL) | Approx. detection rate |
|---|---|
| < 0.5 | ~30–45% |
| 0.5–1.0 | ~55–65% |
| 1.0–2.0 | ~75% |
| > 2.0 | ~90%+ |
Even at low PSA, PSMA PET substantially outperforms CT/bone scan — the reason it is used early in recurrence work-up. (Exact figures vary by agent, cohort, and criteria.)
Interpretation & Decision — What a Positive Scan Changes
- Isolated local (prostate-bed) recurrence → salvage radiotherapy to the bed.
- Limited nodal disease → salvage nodal radiotherapy ± systemic therapy / metastasis-directed therapy.
- Distant / polymetastatic disease → systemic therapy rather than futile local salvage.
PSMA-PET frequently moves patients between these buckets versus conventional imaging. A negative scan at very low PSA does not exclude disease (sub-threshold tumor volume) — short-interval re-imaging as PSA rises often localizes it.
Emerging: PET Phenotype Meets Genomics
An active research direction pairs the PSMA-PET phenotype with tumor genomics (next-generation sequencing) in large biochemical-recurrence cohorts, to explain imaging patterns and refine prognosis. This is emerging, not standard-of-care.
Differential Diagnosis (of PSMA uptake)
Celiac/sympathetic ganglia (retrocrural node mimic), healing ribs/fractures, Paget, fibrous dysplasia, non-prostatic tumors (RCC, HCC, thyroid), neovasculature, and inflammation — PSMA is not prostate-specific.
Reporting Checklist
- State the agent, PSA, and PSA kinetics context.
- Use PROMISE (miTNM) / PSMA-RADS with lesion-level certainty.
- Classify recurrence as local / nodal / distant to direct salvage.
- Explicitly attribute benign/non-prostatic uptake (celiac ganglion, healing bone).
Common Pitfalls
- Celiac ganglion uptake mimicking a retrocrural node — the classic trap.
- Healing rib fractures / benign bone lesions mimicking skeletal metastasis.
- PSMA uptake in non-prostatic tumors and inflammation (not prostate-specific).
- A single false-positive focus upstaging a patient out of curative salvage.
Board Pearls
PSMA PET is the standard for biochemical recurrence, localizing disease when conventional imaging is negative — detection rises steeply with PSA and shorter doubling time (~30–45% below 0.5 ng/mL to ~90%+ above 2.0). Localizing recurrence redirects therapy: isolated local → bed salvage RT; limited nodal → nodal salvage ± systemic/MDT; distant → systemic therapy.
Set pretest expectations by the PSA at scan time. A negative scan at very low PSA does not exclude disease — it may reflect sub-threshold volume, and short-interval re-imaging as PSA rises can localize it. Report with a standardized framework (PROMISE/PSMA-RADS) and lesion-level certainty.
PSMA is not prostate-specific — the celiac ganglion (retrocrural-node mimic), healing ribs, Paget, non-prostatic tumors, and inflammation all take up tracer. A standardized read guards against a single false-positive focus upstaging a patient out of curative salvage. Pairing PSMA phenotype with genomics is an emerging prognostic frontier.
Related Pages
- Tracer: PSMA PET agents; disease: Prostate cancer; therapy: ¹⁷⁷Lu-PSMA-617.
Figure / Diagram Suggestions
- A PSA-vs-detection curve for biochemical recurrence.
- A local/nodal/distant → therapy decision tree.
- A benign-uptake atlas (celiac ganglion, healing rib) vs true recurrence.
Self-Check
Q1. How should you frame the pretest likelihood of a positive PSMA PET at PSA 0.4 ng/mL?
Answer: Roughly 30–45%, rising with higher PSA and shorter PSA doubling time; a negative scan doesn't exclude sub-threshold disease.
Q2. An isolated prostate-bed recurrence is found. How does this change management?
Answer: It directs salvage radiotherapy to the bed rather than empiric systemic escalation.
Q3. A solitary retrocrural focus of PSMA uptake could change staging. What benign structure must you exclude?
Answer: The celiac (sympathetic) ganglion, which mimics a retrocrural node.
Q4. Why does a standardized read (PROMISE/PSMA-RADS) matter in biochemical recurrence?
Answer: It assigns lesion-level certainty, guarding against a single false-positive focus upstaging a patient out of curative salvage.
Evidence & sources
https://nuc.med/psma-biochemical-recurrence/ Report an issue